medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2016, Number 1

<< Back

Biotecnol Apl 2016; 33 (1)

Spreading kinetics of the exogenous porcine surfactant Surfacen® mixed with drugs used in respiratory clinics

Blanco O, Pérez R, Lugones Y, Morilla A, Faure R

Language: English
References: 27
Page: 1521-1525
PDF size: 628.03 Kb.


ABSTRACT

The specific biophysical properties of the surfactant complex, able to adsorb with high efficiency to the air-liquid interface and, through it, quickly travel to the distal airways, becomes the surfactant a potential vehicle for drug delivery by the inhaled route in the treatment of several lung diseases. However it is vital that drugs delivered via lungs did not interfere with the pulmonary surfactant lining layer surface activity. The aim of this study was to evaluate the in vitro effect of N-acetylcysteine, hydrocortisone and amikacin on the interfacial property (spreading) of Surfacen®. The interfacial property of porcine lipid extract, Surfacen®, was evaluated in vitro by Langmuir balance. Measurements were obtained before and after the addition of a low and high concentration of drugs. The drugs do not affect the ability of spreading Surfacen. Future studies are necessary to evaluate all Surfacen biophysical properties in the presence of these drugs.


REFERENCES

  1. Moreno OV, López ML, Dieppa FD, López MAP, Abad AA, Rivero GJ, et al. Estudio de la eficacia del surfacen en el distress respiratorio del recién nacido. Rev Cubana Pediatria. 1999;71((2)):60-71.

  2. Palmer D, Schurch S, Belik J. Effect of budesonide and salbutamol on surfactant properties. J Appl Physiol (1985). 2000;89(3):884-90.

  3. Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008;121(5):e1310-8.

  4. Zhang H, Wang YE, Neal CR, Zuo YY. Differential effects of cholesterol and budesonide on biophysical properties of clinical surfactant. Pediatr Res. 2012;71(4 Pt 1):316-23. REPORT

  5. Adi H, Young PM, Traini D. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. J Pharm Pharmacol. 2012;64(9):1245-53.

  6. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD003794.

  7. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2012;5:CD002057.

  8. Yang CF, Lin CH, Chiou SY, Yang YC, Tsao PC, Lee YS, et al. Intratracheal budesonide supplementation in addition to surfactant improves pulmonary outcome in surfactant-depleted newborn piglets. Pediatr Pulmonol. 2013;48(2):151-9.

  9. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, Demissie S, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340(13):1005-10.

  10. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2007(4):CD002057.

  11. Dani C, Corsini I, Burchielli S, Cangiamila V, Longini M, Paternostro F, et al. Natural surfactant combined with beclomethasone decreases oxidative lung injury in the preterm lamb. Pediatr Pulmonol. 2009;44(12):1159-67.

  12. Yang CF, Jeng MJ, Soong WJ, Lee YS, Tsao PC, Tang RB. Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model. Pediatr Neonatol. 2010;51(4):219-26.

  13. Dani C, Corsini I, Burchielli S, Cangiamila V, Romagnoli R, Jayonta B, et al. Natural surfactant combined with beclomethasone decreases lung inflammation in the preterm lamb. Respiration. 2011;82(4):369-76.

  14. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent. Adv Drug Deliv Rev. 2001;47(2- 3):197-207.

  15. Schwameis R, Erdogan-Yildirim Z, Manafi M, Zeitlinger MA, Strommer S, Sauermann R. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother. 2013;57(10):5151-4.

  16. Sadowska AM, Manuel YKB, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo doseeffects: a review. Pulm Pharmacol Ther. 2007;20(1):9-22.

  17. De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel PM, et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis. 2013;8:569-79.

  18. Manzanares D, Díaz E, Alfonso W, Escobar A, Colomé H, Muñoz MC, et al. Surfactante pulmonar porcino. República de Cuba 1995;A 61:35-42 K.

  19. Blanco O, Cruz A, Ospina OL, Lopez- Rodriguez E, Vazquez L, Perez-Gil J. Interfacial behavior and structural properties of a clinical lung surfactant from porcine source. Biochim Biophys Acta. 2012;1818(11):2756-66.

  20. Schurch S, Green FH, Bachofen H. Formation and structure of surface films: captive bubble surfactometry. Biochim Biophys Acta. 1998;1408(2-3):180-202.

  21. Lopez-Rodriguez E, Perez-Gil J. Structure- function relationships in pulmonary surfactant membranes: from biophysics to therapy. Biochim Biophys Acta. 2014;1838(6):1568-85.

  22. Wang YE, Zhang H, Fan Q, Neal CR, Zuo YY. Biophysical interaction between corticosteroids and natural surfactant preparation: implications for pulmonary drug delivery using surfactant as a carrier. Soft Matter. 2012;8(2):504-11.

  23. Santus P, Corsico A, Solidoro P, Braido F, Marco FD, Scichilone N. Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine. Copd. 2014.

  24. Zhang T, Zhou X. Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review). Experimental and therapeutic medicine. 2014;7(4):763-7.

  25. van ‘t Veen A, Gommers D, Mouton JW, Kluytmans JA, Krijt EJ, Lachmann B. Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity. Br J Pharmacol. 1996;118(3):593-8.

  26. Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B. Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biol Neonate. 2005;88(2):101-8.

  27. Birkun A. Exogenous Pulmonary surfactant as a vehicle for antimicrobials: assessment of surfactant-antibacterial interactions in vitro. Scientifica. 2014;2014.




2020     |     www.medigraphic.com